| http://dbpedia.org/ontology/abstract
|
Tofogliflozin (INN, USAN, codenamed CSG452 … Tofogliflozin (INN, USAN, codenamed CSG452) is an experimental drug for the treatment of diabetes mellitus and is being developed by Chugai Pharma in collaboration with Kowa and Sanofi. It is an inhibitor of subtype 2 sodium-glucose transport protein (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney. As of September 2012, the drug is in Phase III clinical trials. the drug is in Phase III clinical trials.
, トホグリフロジン（Tofogliflozin）は2型糖尿病治療薬のひとつで、阻害薬である。製品名はデベルザ（興和創薬販売、興和製造販売）およびアプルウェイ（サノフィ製造販売）。日本では2014年3月24日に製造承認された。
|
| http://dbpedia.org/ontology/casNumber
|
(anhydrous)
, 1201913-82-7
|
| http://dbpedia.org/ontology/chEMBL
|
2105711
|
| http://dbpedia.org/ontology/fdaUniiCode
|
P8DD8KX4O4
|
| http://dbpedia.org/ontology/kegg
|
D09978
|
| http://dbpedia.org/ontology/pubchem
|
46908928
|
| http://dbpedia.org/ontology/thumbnail
|
http://commons.wikimedia.org/wiki/Special:FilePath/Tofogliflozin_monohydrate_skeletal_3D.svg?width=300 +
|
| http://dbpedia.org/ontology/wikiPageExternalLink
|
http://www.chemspider.com/Chemical-Structure.28530778.html +
, https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL2110731 +
|
| http://dbpedia.org/ontology/wikiPageID
|
38896843
|
| http://dbpedia.org/ontology/wikiPageLength
|
5104
|
| http://dbpedia.org/ontology/wikiPageRevisionID
|
993030672
|
| http://dbpedia.org/ontology/wikiPageWikiLink
|
http://dbpedia.org/resource/Chugai_Pharma +
, http://dbpedia.org/resource/File:Tofogliflozin_skeletal_3D.svg +
, http://dbpedia.org/resource/CHEMBL +
, http://dbpedia.org/resource/Reabsorption +
, http://dbpedia.org/resource/International_nonproprietary_name +
, http://dbpedia.org/resource/Clinical_trial +
, http://dbpedia.org/resource/ChemSpider +
, http://dbpedia.org/resource/Category:SGLT2_inhibitors +
, http://dbpedia.org/resource/Molecular_mass +
, http://dbpedia.org/resource/SGLT2 +
, http://dbpedia.org/resource/United_States_Adopted_Name +
, http://dbpedia.org/resource/Sanofi +
, http://dbpedia.org/resource/Monohydrate +
, http://dbpedia.org/resource/Category:Spiro_compounds +
, http://dbpedia.org/resource/Category:Glucosides +
, http://dbpedia.org/resource/International_Nonproprietary_Name +
, http://dbpedia.org/resource/Kowa_Co. +
, http://dbpedia.org/resource/Diabetes_mellitus +
, http://dbpedia.org/resource/Gliflozin +
, http://dbpedia.org/resource/Category:Isobenzofurans +
, http://dbpedia.org/resource/Sodium-glucose_transport_protein +
, http://dbpedia.org/resource/Anhydrous +
|
| http://dbpedia.org/property/atcPrefix
|
None
|
| http://dbpedia.org/property/c
|
22
|
| http://dbpedia.org/property/casNumber
|
1201913
|
| http://dbpedia.org/property/chembl
|
2105711
|
| http://dbpedia.org/property/chemspiderid
|
28527871
|
| http://dbpedia.org/property/drugName
|
Tofogliflozin monohydrate
|
| http://dbpedia.org/property/h
|
28
|
| http://dbpedia.org/property/iupacName
|
240.0
|
| http://dbpedia.org/property/kegg
|
D09978
|
| http://dbpedia.org/property/legalStatus
|
Investigational
|
| http://dbpedia.org/property/o
|
7
|
| http://dbpedia.org/property/pubchem
|
46908928
|
| http://dbpedia.org/property/smiles
|
CCc1cccCc2ccc3c[C@]4OC3.O
|
| http://dbpedia.org/property/stdinchi
|
1
|
| http://dbpedia.org/property/stdinchikey
|
ZXOCGDDVNPDRIW-NHFZGCSJSA-N
|
| http://dbpedia.org/property/synonyms
|
CSG452
|
| http://dbpedia.org/property/unii
|
P8DD8KX4O4
|
| http://dbpedia.org/property/wikiPageUsesTemplate
|
http://dbpedia.org/resource/Template:CAS +
, http://dbpedia.org/resource/Template:As_of +
, http://dbpedia.org/resource/Template:Reflist +
, http://dbpedia.org/resource/Template:Rp +
, http://dbpedia.org/resource/Template:Sodium-glucose_transporter_modulators +
, http://dbpedia.org/resource/Template:Drugbox +
, http://dbpedia.org/resource/Template:Fdacite +
, http://dbpedia.org/resource/Template:Gastrointestinal-drug-stub +
, http://dbpedia.org/resource/Template:Oral_hypoglycemics_and_insulin_analogs +
, http://dbpedia.org/resource/Template:Clear_left +
|
| http://purl.org/dc/terms/subject
|
http://dbpedia.org/resource/Category:SGLT2_inhibitors +
, http://dbpedia.org/resource/Category:Isobenzofurans +
, http://dbpedia.org/resource/Category:Spiro_compounds +
, http://dbpedia.org/resource/Category:Glucosides +
|
| http://purl.org/linguistics/gold/hypernym
|
http://dbpedia.org/resource/Drug +
|
| http://www.w3.org/ns/prov#wasDerivedFrom
|
http://en.wikipedia.org/wiki/Tofogliflozin?oldid=993030672&ns=0 +
|
| http://xmlns.com/foaf/0.1/depiction
|
http://commons.wikimedia.org/wiki/Special:FilePath/Tofogliflozin_monohydrate_skeletal_3D.svg +
, http://commons.wikimedia.org/wiki/Special:FilePath/Tofogliflozin_skeletal_3D.svg +
|
| http://xmlns.com/foaf/0.1/isPrimaryTopicOf
|
http://en.wikipedia.org/wiki/Tofogliflozin +
|
| http://xmlns.com/foaf/0.1/name
|
Tofogliflozin monohydrate
|
| owl:sameAs |
http://yago-knowledge.org/resource/Tofogliflozin +
, http://sr.dbpedia.org/resource/Tofogliflozin +
, http://sh.dbpedia.org/resource/Tofogliflozin +
, https://global.dbpedia.org/id/XvZg +
, http://ja.dbpedia.org/resource/%E3%83%88%E3%83%9B%E3%82%B0%E3%83%AA%E3%83%95%E3%83%AD%E3%82%B8%E3%83%B3 +
, http://rdf.freebase.com/ns/m.0ryt_r3 +
, http://www.wikidata.org/entity/Q15410175 +
, http://vi.dbpedia.org/resource/Tofogliflozin +
, http://dbpedia.org/resource/Tofogliflozin +
|
| rdf:type |
http://dbpedia.org/class/yago/Agent114778436 +
, http://dbpedia.org/class/yago/Drug103247620 +
, http://www.wikidata.org/entity/Q8386 +
, http://dbpedia.org/class/yago/WikicatSGLT2Inhibitors +
, http://dbpedia.org/class/yago/Substance100020090 +
, http://dbpedia.org/class/yago/WikicatAnti-diabeticDrugs +
, http://dbpedia.org/ontology/Drug +
, http://dbpedia.org/class/yago/Matter100020827 +
, http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#ChemicalObject +
, http://dbpedia.org/class/yago/Inhibitor114724436 +
, http://dbpedia.org/ontology/ChemicalSubstance +
, http://dbpedia.org/class/yago/CausalAgent100007347 +
, http://dbpedia.org/class/yago/PhysicalEntity100001930 +
|
| rdfs:comment |
トホグリフロジン（Tofogliflozin）は2型糖尿病治療薬のひとつで、阻害薬である。製品名はデベルザ（興和創薬販売、興和製造販売）およびアプルウェイ（サノフィ製造販売）。日本では2014年3月24日に製造承認された。
, Tofogliflozin (INN, USAN, codenamed CSG452 … Tofogliflozin (INN, USAN, codenamed CSG452) is an experimental drug for the treatment of diabetes mellitus and is being developed by Chugai Pharma in collaboration with Kowa and Sanofi. It is an inhibitor of subtype 2 sodium-glucose transport protein (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney. As of September 2012, the drug is in Phase III clinical trials. the drug is in Phase III clinical trials.
|
| rdfs:label |
Tofogliflozin
, トホグリフロジン
|
